Neurooncology2016

Protected by Copyscape Unique Content Check
Published: 04th June 2017
Views: N/A

About the conference:
We are happy to welcome you for the official website of International Conference on Neuro-Oncology during July 21-23, 2016 at Brisbane, Australia. The aim of the Conference is to provide a platform to academicians and practitioners from multiple disciplines to debate and deliberate on social change that is encompassed by innovation and technology.
Geographically market is segmented into Europe, North America, Latin America, Asia pacific, and Middle East and Africa. According to market study, Market Value for Neuro Oncology (i.e on Brain Cancer and CNS Tumors) will be more than double to $ 623 Million by 2020. A major part of research is going on the top Universities on Neuro-Oncology across the globe. Many companies are associated with various diagnostic instruments and other therapeutics. Besides this various societies and research labs are also associated in this research field.
The incidence rate of all primary malignant and non-malignant brain cancer and CNS tumors is 21.42 cases per 100,000 for a total count of 343,175 incident tumors, (7.25 per 100,000 for malignant tumors for a total count of 115,799 incident tumors and 14.17 per 100,000 for non-malignant tumors for a total count of 227,376 incident tumors). The rate is higher in females (23.26 per 100,000 for a total count of 198,212 incident tumors) than in males (19.42 per 100,000 for a total count of 144,963 incident tumors)
OMICS International is one of the leading organisation in conducting worldwide conferences which organizes 1000+ Global Events inclusive of 350+ Conferences, 500+ Workshops and 200+ Symposiums on various topics of Science & Technology across the globe with support from 1000 more scientific societies and Publishes 500+ Open Access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Scientific Sessions:
Overview of Neuro Oncology
Quality of life is an important area of clinical Neuro oncology that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies. Neuro-oncology is the study of brain cancer and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life-threatening.
Central Nervous System
The central nervous system is the part of the nervous system that consists of the brain and spinal cord. The nervous system is exposed to various harmful disorders. Central Nervous System covers its mechanism, function, Metastatic diseases, Cancers, Neurons and Sensory Receptors, Neurological Disorders, Neurodegenerative disease and Imaging agents to CNS tumors. Global Central Nervous System Drugs market to grow at a CAGR of -3.2% over the period 2011-2015. The global central nervous system (CNS) therapeutics market has been forecast to reach US$133 billion by the year 2018, which increases in disease prevalence rates due to increase in population, introduction of new drugs, and increased outgo on healthcare.
Brain Cancer
Brain Cancer market is segmented on the basis of diagnosis and therapeutics. A brain cancer involves the growth of abnormal cells in the tissues of the brain. Brain tumors can be either benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Primary brain cancer develops from cells within the brain and others are metastatic, starts somewhere else in the body and move to the brain. Primary brain cancer involves malignant tumor, Brain stem tumors, germ cell tumor, pituitary adenomas, Tumor development, DIPG, Cellular biology of brain cancer, primary CNS lymphomas, Pathophysiology and Risk factors of brain cancer and prognosis of brain tumors.
Demand for Brain Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, its been observed that both production and demand will continue to grow. Key market players which make a part in this field are Antisense Pharma, Novartis AG, AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Hoffmann-La Roche Ltd, Genentech and others.
Glioblastoma
Glioblastoma multiforme (GBM) (named as glioblastoma) is a invasive glioma which is developed from star-shaped glial cells (i.e. astrocytes and oligodendrocytes) that support the health of the nerve cells within the brain. Glioblastoma tumors are usually highly malignant (i.e. cancerous) and also called as gradeIV tumors. Almost 1 in 5 tumors in the brain are glioblastoma. Men are more likely to get them than women and chances go up with age. The most common symptoms are usually caused by increased pressure in the brain. Depending on the location of the tumor, patients develop variety of other symptoms. Glioblastoma represents about 15.4% of all primary brain cancers and about 60-75% of all astrocytoma. They increase in prevalence with the age, and affect will be more men than women.
The global glioblastoma treatment market was highly valued at USD $0.34 billion in 2013 and is estimated to reach USD $0.91 billion by 2022 at a CAGR of 11.4% from 2014 to 2022. According to the U.S National Cancer Institute, in year 2015 there will be 22,850 cases expected growing at 1.4% rate when compared to 2014 and around 15,320 deaths growing at 2.6% comparing with last year growth rate. Glioblastoma is considered as the most advancing form of brain cancer which grows rapidly and form glioma which represents overall 15.4% of all primary brain tumors and about 60% - 75% of all astrocytoma.
Metastatic Cancer:
When cancer develops elsewhere in the body and spreads (metastasizes) to the brain, which is called as secondary brain tumor, or metastatic brain cancer. Brain metastases (secondary brain tumors) occur in approximately 15% of cancer patients as a result of haematogenous dissemination of cancer, and the incidence may be rising because of better control of systemic disease.
Approximately 10–20% of all brain metastases are single tumors. Sometimes metastatic cancer causes multiple tumors. A metastatic brain cancer is usually found when a cancer patient begins to experience neurological symptoms and a brain scan (CT or MRI) is ordered. Fewer than 10% of all brain cancers are found before the primary cancer is diagnosed.
Metastatic brain tumors are the most common brain tumor in adults. About 85% of metastatic lesions are located in the cerebrum (the top, largest component of the brain) and 15% are located in the cerebellum (the bottom, back part of the brain). The incidence begins to increase in those ages 45–64 years and is highest in people over 65 years of age. The most common brain metastases are Malenoma, Intracranial Metastasis, Skull and spinal Metastasis. Although Melanoma spreads to the brain more commonly in males than in females. There three main categories of treatments include radiation therapy, surgery, and chemotherapy.
Angiogenesis:
Angiogenesis plays a critical role in the growth and spread of cancer, it also plays a major role in the transition of tumors from a benign state to a malignant (cancerous), leading to the use of angiogenesis inhibitors in the treatment of cancer. These are drugs that block the development of normal new blood vessels, which is known as angiogenesis. The main application of angiogenesis inhibitors in Neuro-oncology is increasing. Cellular and molecular interactions driving the Angiogenesis process.. A number of new drugs that target different aspects of the Angiogenic cascade have been identified and are now in clinical trials in children with primary brain tumors. It mainly includes tumor angiogenesis and anti-angiogenic therapies.
Radiation Oncology:
Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It disclose findings in molecular and cellular radiation oncology, radiation technology, radiation physics, and clinical oncology. Significant developments in radiation oncology have taken place in recent years. Radiotherapy is a treatment procedure that involves the use of high-energy radiation.
The global radiation oncology market is highly competitive and marked by the presence of several global and local players. The major key market players in the global radiation oncology market are Varian Medical Systems, Accuracy Inc., Electa AB, and Siemens Healthcare.
Diagnosis and Neuro Imaging:
The primary method which is used in the initial diagnosis(Pet Scan and , monitoring of response, and process of progression in Neuro-oncology is neuroimaging techniques. Neuro imaging has enabled great progress in the diagnosis of brain cancer, as well as finding useful application in medical research and practice. Emphasis is on the strength and limitations of the current imaging standards and on an overview of several advanced imaging methods including Radioactive compounds in Neuroimaging, Structural and functional imaging, Diffuse optical imaging , Computed tomography, Magnetic resonance imaging, Positron and emission tomography(Pet scan). Basic physical principles behind each imaging method are briefly presented, along with in-depth discussion of clinical application and potential pitfalls of each technique. Diagnosis of brain cancer plays a major role in the current market.
The Global cancer diagnostics market is expected to grow at a CAGR of 7.6% during the forecast period of 2014 to 2020. In 2013, the huge global cancer diagnostics market was valued at US$100,994.5 million and is expected value to be worth of US$168,649.3 million by 2020.The increasing tendency of cancer is the main primary factor of global cancer diagnostics market. According to the World Health Organisation, the number of major cancer cases is projected to grow by approximately 70% in the next two decades. Increasing the number of brain cancer cases will fuel the growth of several sectors related to cancer diagnostics. The segment of cancer imaging diagnosis is anticipated to grow at a CAGR of 8.2%. Imaging for cancer diagnosis has taken centre stage in worldwide efforts aimed at cancer detection and prevention.
Cancer Pain Management
About one-third of patients are being treated for cancer pain, which leads to many different forms. It may be short-lived or long-lasting, mild or severe, or affect on few organs, bones or organ system. Since each patient’s pain is unique, it is determined that cancer pain management treatment plans must be adapt to address individual needs. A market intelligence company based in the U.S, states that the Global pain management devices market was estimated at US$2.0 billion in 2011 and, estimated to growing at a CAGR of 13.1% from 2011 to 2018, is predicted to reach the value of US$5.0 billion by 2018.
Pediatric Neuro-oncology
Pediatric Neuro-oncology is a fast developing field. Brain tumors are the cause of cancer-related deaths among children. Brain cancer which is the most common solid malignancy in children. Their bodies and brains are still developing. Their tumors are different. The common childhood brain cancers are not the same as the most common adult brain cancers. Though they are rare, brain tumors are very common form of solid tumors among children under the age of 15 and represent about 20% of all childhood cancers.
Childhood tumors frequently appear in different locations and behave differently than brain tumors appearing in adults. Treatment options are different and can be strongly influenced by the age of the child. Children suffering from brain cancer may also have a much better prognosis than adults with a similar condition. The common types of brain tumors in children are Neurofibromatosis, Primitive Neuroectodermal tumor, Leukemia, Neuroblastoma, Medulloblastoma, Ependymoma and Astrocytoma.
Survival rates for brain tumors vary widely depending on the type of tumor and other factors, including age. Five-year survival rates range from 66% for children ages 0 - 19 years to 5% for adults age 75 years and older. Advancements in treatment have dramatically increased survival rates for children with brain tumors. About 75% of children survive at least 5 years after being diagnosed with a brain tumor. Brain cancers account for about 15% of pediatric cancers and are the second most common type of cancer in children. The specific treatment and prognosis depends on the grade, type, and location of the tumor. Depending on the type of tumor and the timeliness of diagnosis, the 5 year survival growth rate is 40-80%.
Neurosurgery:
Neurosurgery is a complex surgical procedure that involves treatment, diagnosis, and rehabilitation of disorders affecting any region of the nervous system. Some of the most common Neurosurgeries are skull base surgery, Image Guided Surgery, Laser Surgery , spinal Neurosurgery and Neurosurgical treatment. The Global Neurosurgery market is expected to grow 11.71% over the period of 2014-2019.
Tumour Heterogeneity:
Tumour heterogeneity relate differences between tumours of the same type in different patients, and also difference between cancer cells within a tumour cells can show distinct including cellular morphology, motility, gene expression, proliferation, metabolism, and metastatic potential. This process occurs both between tumours which is called as inter-tumour heterogeneity and within tumours called as intra-tumour heterogeneity. It plays a major role in brain Cancer.
Genetic and epigenetic differences between cancer cells within a tumour might explain why some tumour cells remain present in the patient even after cancer treatment has finished. Most current efforts are focused on understanding heterotypic interactions between tumor cells and surrounding normal cells, which is known about the interactions between and among heterogeneous tumor cells within a neoplasm. Tumor Heterogenisity covers Inter- intra tumour heterogeneity, Cancer Stem Cells, Brain Tumor Microenvironment, Experimental- Sequencing, Genetic Heterogeneity and Implications and challenges.
Therapeutic Approaches:
Brain cancer market is segmented on the basis of diagnosis and therapeutics. Major research is going on targeted Therapies for Brain Cancer. On the basis of treatment the market is segmented into surgeries, radiation therapy, immunotherapy, chemotherapy, and targeted therapy. Therapeutic approaches include Chemotherapy, Intensity modulated radiation therapy, palliative care, vaccine therapy, surgical delivery, Molecular pathology for clinician and challenges in therapy.

Global cancer drugs and treatments market will reach $143.7 billion by 2023. The Anti-cancer treatment market is already worth $77.4 billion (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development.
Clinical Trials and Drug Targeting:
Brain Cancer clinical trials are research studies that test new and better ways to prevent, diagnose and treat Brain cancer. A world-first human trial has been set to begin in Brisbane and Melbourne has the potential to be one of the biggest breakthroughs in the treatment of brain cancer, researchers say. According to the Cure Brain Cancer Foundation worth of $500,000 provided to the study over the next three years.
The Centre for Neuro-Oncology offers the latest advances in care for adult patients with brain tumors or spinal cord tumors, as well as for neurologic complications of brain cancer and its treatments. The Australian Government is supporting Australia’s capacity to develop industry-independent cancer clinical trials.

This article is copyright


Report this article Ask About This Article


Loading...
More to Explore